Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: t(8;21) and inv(16) represent different clinical outcomes
- 26 February 2009
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 113 (9), 2096-2103
- https://doi.org/10.1182/blood-2008-03-145862
Abstract
We analyzed 338 adult patients with acute myeloid leukemia (AML) with t(8;21) and inv(16) undergoing stem cell transplantation (SCT) who were registered in the Japan Society for Hematopoietic Cell Transplantation database. At 3 years, overall survival (OS) of patients with t(8;21) and inv(16) was 50% and 72%, respectively (P = .002). Although no difference was observed when restricted to allogeneic SCT in first complete remission (CR; 84% and 74%), OS of patients with t(8;21) and inv(16) undergoing allogeneic SCT in second or third CR (45% and 86% at 3 years; P = .008) was different. OS was not different between patients in first CR who received allogeneic SCT and those who received autologous SCT for both t(8;21) AML (84% vs 77%; P = .49) and inv(16) AML (74% vs 59%; P = .86). Patients with inv(16) not in CR did better after allogeneic SCT than those with t(8;21) (70% and 18%; P = .03). Patients with t(8;21) and inv(16) should be managed differently as to the application of SCT. SCT in first CR is not necessarily recommended for inv(16). For t(8;21) patients in first CR, a prospective trial is needed to clarify the significance of autologous SCT and allogeneic SCT over chemotherapy.This publication has 32 references indexed in Scilit:
- HLA-Identical Sibling Allogeneic Transplants versus Chemotherapy in Acute Myelogenous Leukemia with t(8;21) in First Complete Remission: Collaborative Study between the German AML Intergroup and CIBMTRTransplantation and Cellular Therapy, 2008
- Clinical characteristics and outcomes in patients with t(8;21) acute myeloid leukemia in JapanLeukemia, 2007
- Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcriptsBlood, 2007
- Impact of Cytogenetics on Outcome of De Novo and Therapy-Related AML and MDS after Allogeneic TransplantationTransplantation and Cellular Therapy, 2007
- The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocationsBritish Journal of Haematology, 2006
- Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemiaBlood, 2004
- Repetitive Cycles of High-Dose Cytarabine Benefit Patients With Acute Myeloid Leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): Results from CALGB 8461Journal of Clinical Oncology, 2004
- Characteristics of t(8;21) acute myeloid leukemia (AML) with additional chromosomal abnormality: concomitant trisomy 4 may constitute a distinctive subtype of t(8;21) AMLLeukemia, 2003
- Autologous stem cell transplantation for advanced acute myeloid leukemiaBone Marrow Transplantation, 2002
- Geographic heterogeneity of cellular characteristics of acute myeloid leukemia: a comparative study of Australian and Japanese adult casesLeukemia, 2000